Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AUTL 
Autolus Therapeutics Ltd (AUTL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: AUTL (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $9.86
Year Target Price $9.86
| 8 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.69% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 614.78M USD | Price to earnings Ratio - | 1Y Target Price 9.86 |
Price to earnings Ratio - | 1Y Target Price 9.86 | ||
Volume (30-day avg) - | Beta 1.74 | 52 Weeks Range 1.10 - 5.00 | Updated Date 06/29/2025 |
52 Weeks Range 1.10 - 5.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -726.31% |
Management Effectiveness
Return on Assets (TTM) -20.28% | Return on Equity (TTM) -49.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 158572781 | Price to Sales(TTM) 68.23 |
Enterprise Value 158572781 | Price to Sales(TTM) 68.23 | ||
Enterprise Value to Revenue 17.6 | Enterprise Value to EBITDA 0.03 | Shares Outstanding 266138000 | Shares Floating 119066344 |
Shares Outstanding 266138000 | Shares Floating 119066344 | ||
Percent Insiders 18.09 | Percent Institutions 91.8 |
Analyst Ratings
Rating 4.8 | Target Price 9.86 | Buy 2 | Strong Buy 8 |
Buy 2 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Autolus Therapeutics Ltd
Company Overview
History and Background
Autolus Therapeutics Ltd was founded in 2014, focusing on developing programmed T cell therapies (CAR-T) for cancer. It has achieved milestones in clinical trial advancements and collaborations with pharmaceutical companies.
Core Business Areas
- Programmed T Cell Therapies: Development of CAR-T cell therapies targeting various hematological malignancies and solid tumors.
Leadership and Structure
The company is led by a management team with expertise in oncology and biotechnology. The organizational structure includes research and development, clinical operations, and commercialization departments.
Top Products and Market Share
Key Offerings
- Obe-cel: A CD19 CAR-T cell therapy in development for adult B-cell acute lymphoblastic leukemia (ALL). Currently in Phase 2 clinical trials. Competitors include Kite Pharma's Tecartus and Novartis' Kymriah.
Market Dynamics
Industry Overview
The CAR-T cell therapy market is rapidly growing, driven by advancements in cancer immunotherapy. It's characterized by high treatment costs and significant potential for remission in hematological cancers.
Positioning
Autolus Therapeutics Ltd is positioned as a key player in the next-generation CAR-T cell therapy market, focusing on overcoming limitations of existing therapies. Competitive advantages include a differentiated CAR design aimed at improved safety and efficacy.
Total Addressable Market (TAM)
The global CAR-T cell therapy market is projected to reach tens of billions of dollars in the next decade. Autolus is positioned to capture a portion of this TAM through successful clinical trials and commercialization of its CAR-T therapies.
Upturn SWOT Analysis
Strengths
- Innovative CAR-T platform
- Strong clinical data in specific indications
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited commercialized products
- High R&D expenses
- Dependence on clinical trial success
- Intense competition
Opportunities
- Expansion into new cancer indications
- Development of next-generation CAR-T technologies
- Potential for partnerships and acquisitions
- Addressing solid tumors with CAR-T therapies
Threats
- Regulatory hurdles
- Clinical trial failures
- Competition from established pharmaceutical companies
- High cost of therapy limiting market access
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
Competitive Landscape
Autolus offers a differentiated CAR-T platform, but faces competition from companies with approved therapies and established market presence. A key advantage is the potential for improved safety and efficacy of its CAR designs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the progress of their pipeline of CAR-T cell therapies.
Future Projections: Future projections are dependent on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include progressing obe-cel through clinical trials and expanding their CAR-T platform.
Summary
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in CAR-T cell therapies. While it has innovative technologies and strong clinical data for specific indications, it faces challenges from larger, established competitors and the high costs of R&D. Success hinges on favorable clinical trial results and regulatory approvals. The company's focus on next-generation CAR-T technologies and strategic partnerships could propel future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Autolus Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-06-22 | CEO & Director Dr. Christian Martin Itin Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 647 | Website https://www.autolus.com |
Full time employees 647 | Website https://www.autolus.com | ||
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.